Publications by authors named "Juluri Suresh"

Claim this Profile
N
Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.
Sven Ruf, Sridharan Rajagopal, Sanjay Venkatachalapathi Kadnur, Mahanandeesha S Hallur, Shilpa Rani, Juluri Suresh

Sci Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells.
Hiraganahalli Bhaskar Deepak, Nellikalaya Shreekrishna, Zaheerbasha Sameermahmood, Niranjan Naranapur Anand, Raghotham Hulgi, Juluri Suresh

J Biol Methods· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry.
Sreekanth Dittakavi, Lavanya Mahadevan, Devaraj V Chandrashekar, Ravi Kanth Bhamidipati, Juluri Suresh

Biomed Chromatogr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.
Sven Ruf, Mahanandeesha Siddappa Hallur, Nisha K Anchan, Indu N Swamy, Karthikai Raj Murugesan, Juluri Suresh

Bioorg Med Chem Lett· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders.
Aimo Kannt, Sridharan Rajagopal, Sanjay Venkatachalapathi Kadnur, Juluri Suresh, Ravi Kanth Bhamidipati

Sci Rep· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of monkey and mouse nicotinamide N-methyltransferase (NNMT) bound with end product, 1-methyl nicotinamide.
Srinivasan Swaminathan, Swarnakumari Birudukota, Manish Kumar Thakur, Reejuana Parveen, Saravanan Kandan, Suresh Juluri

Biochem Biophys Res Commun· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease.
S Barret Kalindjian, Sanjay V Kadnur, Christopher A Hewson, Chandregowda Venkateshappa, Suresh Juluri

J Med Chem· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.
Sudhir Sharma, Angaru Sowjanya, Manju Kumari, Raichur Suryaprakash, Gershome Cynthia, Juluri Suresh

Life Sci· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents.
Bhargavi N L Vajja, Suresh Juluri, Manju Kumari, Labonyamoy Kole, Ranjan Chakrabarti

Int Immunopharmacol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Ranjan Chakrabarti, Parimal Misra, Reeba K Vikramadithyan, Mamnoor Premkumar, Jagadheshan Hiriyan, Juluri Suresh

Eur J Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Ranjan Chakrabarti, Reeba K Vikramadithyan, Parimal Misra, Jagadheshan Hiriyan, Suryaprakash Raichur, Juluri Suresh

Br J Pharmacol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
Parimal Misra, Ranjan Chakrabarti, Reeba K Vikramadithyan, Gopalakrishnan Bolusu, Suresh Juluri

J Pharmacol Exp Ther· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Reeba K Vikramadithyan, Jagadheshan Hiriyan, Juluri Suresh, Cynthia Gershome, Ravi K Babu

Obes Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis